Tabla de contenido
Diapositiva PPT
Diapositiva PPT
Diapositiva PPT
Diapositiva PPT
Angiotensin II effects at the AT1 and AT2 receptors
SRA. LOCALIZACION Y FUNCION DE LOS RECEPTORES AT1 RENALES
RECEPTORES AT1
RECEPTORES AT2
Diapositiva PPT
Beneficios del bloqueo SRA para NEFROPROTECCION
Diapositiva PPT
Diapositiva PPT
The Renin-Angiotensin System showing ACE and non-ACE pathways
Diapositiva PPT
Diapositiva PPT
Diapositiva PPT
RAMIPRIL EN LA PREVENCION DE LA IRCT.ESTUDIO REIN (GISEN, Lancet 1997; RUGGENENTI et al JASN 2001)
Ramipril prolongs life and cost reffective in chronic proteinuric nephropathies Ruggenenti et al Kidney Int 2001, 59:286-294
IECA EN LA PREVENCION DE LA IRCT EN NIgA (Praga et al, JASN 2003;14:1578-1583)
FOSINOPRIL EN PROGRESION DE LA IRC (ESTUDIO ESPIRAL) (Marin et al 2002; J. Hypertens 2001; 10:1871-6
Diapositiva PPT
Diapositiva PPT
Incidence of ESRD Due to Diabetes in Europe
Mechanistic Rationale for RAS Blockade in Diabetic Renal Disease
Course of diabetic renal disease
Diapositiva PPT
Effect of ACE Inhibition on Nephropathy in Patients with Type 1 Diabetes
CAPTOPRIL EN DM-1. Lewis et al
Benefits of ACE Inhibition in Type 2 Diabetes
Diapositiva PPT
Diapositiva PPT
Effect of Losartan on Microalbuminuria
Antiproteinuric Effect of Angiotensin II Receptor Antagonists (IgA N)
Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Praga et al, NDT 2003;18:1806-13
Diapositiva PPT
LOSARTAN vs ENALAPRIL EN DM-2 CON ND (AM Castelao et al. JASN 1999, 10: 127 A).
PRIME Time Course of Type 2 Diabetic Renal Disease
IRMA 2 Study design
IRMA 2 Primary Endpoint Time to Overt Proteinuria
IRMA 2 Primary Endpoint Development of Overt Proteinuria
IRMA 2 Normalization of Urinary Albumin Excretion Rate
IDNT Study Design
IDNT Primary Endpoint Time to Doubling of Serum Creatinine, ESRD, or Death
RENAAL Study Design
Diapositiva PPT
RENAAL Primary Composite Endpoint Doubling of Serum Creatinine/ESRD/Death
Diapositiva PPT
PRIME Clinical Impact
Diapositiva PPT
Diapositiva PPT
BLOQUEO DOBLE DE SRA. ENFERMEDAD RENAL NO DIABETICA DOSIS ANTIPROTEINURICAS OPTIMAS. Laverman et al. Kidney Int 2002;62:1020-25)
BLOQUEO DOBLE SRA ENFERMEDAD RENAL NO DIABETICA (ERND) Estudio COOPERATE ( Nakao et al , Lancet 2002)
Effects of dual blockade of the RAS in primary proteinuric nephropathies. Luño et al. Kidney Int.62 (supl.82):47-52
BLOQUEO DOBLE SRA DM-1 + ND Jacobsen et al JASN 2003;14:992-999
BLOQUEO DOBLE SRA DM-2 + ND (MALB) Estudio CALM. (Mogensen et al, Br M J2000;321:1440-1444)
BLOQUEO TRIPLE IECA / ARA II / ESTATINA Zoja et al, JASN 2002;13:2898-2908
BLOQUEO TRIPLE (Zoja et al)
Diapositiva PPT
OLMESARTAN
Diapositiva PPT
Diapositiva PPT
Diapositiva PPT
Diapositiva PPT
Diapositiva PPT
Diapositiva PPT
Diapositiva PPT
Effect of different doses of OLMESARTAN Medoxomil compared to LOSARTAN on proteinuria, renal function and inflammatory markers in type 2 Diabetics with NEPHROPATHY
EPLERENONA
SIGNIFICACION CLINICA DEL BLOQUEO DE LA ALDOSTERONA
BLOQUEO DOBLE A-ALD
EPLERENONE (SC-66110)
EPLERENONA
Effect of Eplerenone coadministered with a fixed dose of Enalapril in Type 2 Diabetic patiens with microalbuminuria
Diapositiva PPT
EPLERENONE IN TYPE 2 DM + mALB
CONCLUSIONES.1.
CONCLUSIONES.2. +
|